Skip to main content
. Author manuscript; available in PMC: 2010 Feb 3.
Published in final edited form as: Cancer Cell. 2009 Feb 3;15(2):103–113. doi: 10.1016/j.ccr.2009.01.001

Figure 7. IL-6 signaling stimulates tumor formation and growth.

Figure 7

(A) Scheme of treatment with IL-6 agonists during late stage of CAC growth. Mice were i.p. injected with 2 μg Hyper-IL-6 or 5 μg recombinant IL-6 every 3 days after the last DSS cycle. Tumors were analyzed on day 100 after AOM injection. (B) Numbers of tumors larger than > 2mm. Results are averages ± s.d. (n=7), * p<0.05. (C) Tumor multiplicity; Results are averages ± s.d., NS- not significant. (D) Scheme of treatment with IL-6 agonists during CAC induction. Mice were i.p. injected with the same amounts of IL-6 agonists as in (A), on day 1, 5 and 8 of each DSS cycle. Tumors were analyzed 100 days after AOM injection. (E) Average tumor load. Results are averages ± s.d. (n=6). * p<0.05. (F) Tumor multiplicity. Results are averages ± s.d. (n=6). * p<0.05. (G) Immunoblot analysis of colonic lysates from mice treated with hyper-IL-6, rec IL-6 or PBS after exposure to 2.5% DSS for 7 days. Mice were sacrificed on day 10 30 min after the last treatment.